Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Hematology
Disease Category: Myelodysplastic Syndromes (MDS)

Trial Information

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

A Phase I, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults

Ages Eligible for Study: 18 Years and older
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Men and women 18 years of age or older
• Patients who are scheduled to receive an autologous or allogeneic hematopoietic cell transplant within 60 days of enrollment
• HIV-infected patients with a baseline CD4 cell count < or = to 200 cells/mm3
• Patients with hematologic malignancies
• Patients who are receiving chemotherapy for breast, colorectal, or lung malignancies

Exclusion Criteria:

• History of allergy to any vaccine component
• Prior history of herpes zoster
• Prior history of receipt of any varicella or zoster vaccine

David Woolner
Merck Sharp & Dohme (Australia) Pty Ltd.
Located in:
South Granville NSW 2142
Australia
Phone: 64-9-523-6075

View Google Map

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.